NMTC Fundamental Analysis - NEUROONE MEDICAL TECHNOLOGIE

Fundamental Rating

Overall NMTC gets a fundamental rating of 3 out of 10. We evaluated NMTC against 188 industry peers in the Health Care Equipment & Supplies industry. NMTC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NMTC shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NMTC has reported negative net income.

NMTC had a negative operating cash flow in the past year.

In the past 5 years NMTC always reported negative net income.

NMTC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -49.33%, NMTC is doing worse than 67.02% of the companies in the same industry.

Looking at the Return On Equity, with a value of -65.26%, NMTC is in line with its industry, outperforming 46.28% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-49.33%
ROE	-65.26%
ROIC	N/A

ROA(3y)-151.29%

ROA(5y)-173.14%

ROE(3y)-597.5%

ROE(5y)-520.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 70.14%, NMTC is doing good in the industry, outperforming 77.66% of the companies in the same industry.

NMTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	70.14%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, NMTC has more shares outstanding

The number of shares outstanding for NMTC has been increased compared to 5 years ago.

The debt/assets ratio for NMTC is higher compared to a year ago.

2.2 Solvency

NMTC has an Altman-Z score of -2.10. This is a bad value and indicates that NMTC is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -2.10, NMTC perfoms like the industry average, outperforming 40.96% of the companies in the same industry.

NMTC has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.

With a decent Debt to Equity ratio value of 0.13, NMTC is doing good in the industry, outperforming 63.83% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.13
Debt/FCF	N/A
Altman-Z	-2.1

ROIC/WACCN/A

WACC8.52%

2.3 Liquidity

A Current Ratio of 7.13 indicates that NMTC has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 7.13, NMTC belongs to the top of the industry, outperforming 86.17% of the companies in the same industry.

A Quick Ratio of 5.80 indicates that NMTC has no problem at all paying its short term obligations.

NMTC has a Quick ratio of 5.80. This is amongst the best in the industry. NMTC outperforms 85.64% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.13
Quick Ratio	5.8

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NMTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.67%, which is quite impressive.

NMTC shows a strong growth in Revenue. In the last year, the Revenue has grown by 142.96%.

NMTC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 143.22% yearly.

EPS 1Y (TTM)67.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%69.1%

Revenue 1Y (TTM)142.96%

Revenue growth 3Y143.22%

Revenue growth 5YN/A

Sales Q2Q%105.38%

3.2 Future

NMTC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.96% yearly.

Based on estimates for the next years, NMTC will show a very strong growth in Revenue. The Revenue will grow by 34.68% on average per year.

EPS Next Y72.62%

EPS Next 2Y28.64%

EPS Next 3Y19.96%

EPS Next 5YN/A

Revenue Next Year27.11%

Revenue Next 2Y26.81%

Revenue Next 3Y28.25%

Revenue Next 5Y34.68%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NMTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NMTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as NMTC's earnings are expected to grow with 19.96% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y28.64%

EPS Next 3Y19.96%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NMTC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEUROONE MEDICAL TECHNOLOGIE

NASDAQ:NMTC (12/1/2025, 8:00:02 PM)

After market: 0.68 0 (-0.16%)

0.6811

-0.01 (-1.97%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)08-14 2025-08-14/bmo

Earnings (Next)12-10 2025-12-10/amc

Inst Owners33.63%

Inst Owner Change6.62%

Ins Owners4.18%

Ins Owner Change-0.8%

Market Cap34.05M

Revenue(TTM)9.63M

Net Income(TTM)-5.34M

Analysts85

Price Target2.27 (233.28%)

Short Float %0.11%

Short Ratio0.12

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)32.46%

Min EPS beat(2)23.75%

Max EPS beat(2)41.18%

EPS beat(4)3

Avg EPS beat(4)47.24%

Min EPS beat(4)-34.8%

Max EPS beat(4)158.82%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-25.92%

Min Revenue beat(2)-43.22%

Max Revenue beat(2)-8.62%

Revenue beat(4)1

Avg Revenue beat(4)-21.92%

Min Revenue beat(4)-88.49%

Max Revenue beat(4)52.66%

Revenue beat(8)2

Avg Revenue beat(8)-19.9%

Revenue beat(12)4

Avg Revenue beat(12)-5.35%

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)53.45%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)11.54%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)12.25%

Revenue NY rev (1m)0%

Revenue NY rev (3m)2.28%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.54
P/FCF	N/A
P/OCF	N/A
P/B	4.16
P/tB	4.19
EV/EBITDA	N/A

EPS(TTM)-0.15

EYN/A

EPS(NY)-0.15

Fwd EYN/A

FCF(TTM)-0.08

FCFYN/A

OCF(TTM)-0.08

OCFYN/A

SpS0.19

BVpS0.16

TBVpS0.16

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-49.33%
ROE	-65.26%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	70.14%
FCFM	N/A

ROA(3y)-151.29%

ROA(5y)-173.14%

ROE(3y)-597.5%

ROE(5y)-520.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.89

Health

		Industry Rank	Sector Rank
Debt/Equity	0.13
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	42.13%
Cap/Sales	1.16%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.13
Quick Ratio	5.8
Altman-Z	-2.1

F-Score5

WACC8.52%

ROIC/WACCN/A

Cap/Depr(3y)158.25%

Cap/Depr(5y)160.45%

Cap/Sales(3y)9.28%

Cap/Sales(5y)12.64%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)67.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%69.1%

EPS Next Y72.62%

EPS Next 2Y28.64%

EPS Next 3Y19.96%

EPS Next 5YN/A

Revenue 1Y (TTM)142.96%

Revenue growth 3Y143.22%

Revenue growth 5YN/A

Sales Q2Q%105.38%

Revenue Next Year27.11%

Revenue Next 2Y26.81%

Revenue Next 3Y28.25%

Revenue Next 5Y34.68%

EBIT growth 1Y53.64%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-23.15%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y56.25%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y55.54%

OCF growth 3YN/A

OCF growth 5YN/A

NEUROONE MEDICAL TECHNOLOGIE / NMTC FAQ

What is the fundamental rating for NMTC stock?

ChartMill assigns a fundamental rating of 3 / 10 to NMTC.

What is the valuation status for NMTC stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUROONE MEDICAL TECHNOLOGIE (NMTC). This can be considered as Overvalued.

What is the profitability of NMTC stock?

NEUROONE MEDICAL TECHNOLOGIE (NMTC) has a profitability rating of 1 / 10.

What is the expected EPS growth for NEUROONE MEDICAL TECHNOLOGIE (NMTC) stock?

The Earnings per Share (EPS) of NEUROONE MEDICAL TECHNOLOGIE (NMTC) is expected to grow by 72.62% in the next year.

NEUROONE MEDICAL TECHNOLOGIE (NMTC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

NEUROONE MEDICAL TECHNOLOGIE / NMTC FAQ

What is the fundamental rating for NMTC stock?

What is the valuation status for NMTC stock?

What is the profitability of NMTC stock?

What is the expected EPS growth for NEUROONE MEDICAL TECHNOLOGIE (NMTC) stock?